MEASUREMENT OF THE CLASS-III ANTIDYSRHYTHMIC DRUG, UK-68,798, IN PLASMA BY RADIOIMMUNOASSAY

被引:26
|
作者
WALKER, DK
AHERNE, GW
ARROWSMITH, JE
CROSS, PE
KAYE, B
SMITH, DA
STOPHER, DA
WILD, W
机构
[1] GUILDHAY ANTISERA LTD,RIVERSIDE BUSINESS CTR,UNIT 6,GUILDFORD GU1 4UG,SURREY,ENGLAND
[2] PFIZER LTD,CENT RES,DEPT DISCOVERY CHEM,SANDWICH CT13 9NJ,KENT,ENGLAND
关键词
CLASS-III ANTIDYSRHYTHMIC DRUG,UK-68,798; RADIOIMMUNOASSAY; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY;
D O I
10.1016/0731-7085(91)80137-X
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A sensitive radioimmunoassay (RIA) for the specific determination of 1-(4-methanesulphonamidophenoxy)-2-[N-(4-methanesulphonamido-phenethyl)-N-methylamino]ethane (UK-68,798), a novel class III antidysrhythmic agent, in human plasma is described. Specific antisera were raised in sheep using desmesyl-UK-68, 798-succinate-ovalbumin conjugate as the antigenic hapten carrier protein. The antisera produced exhibited high specificity for UK-68, 798 compared with known metabolites from animals, other antidysrhythmic agents and co-administered drugs. Good correlation was found in a comparison of the RIA method with a high-performance liquid chromatography (HPLC) method (r = 0.997) and a 10-fold lower limit of determination was observed for the RIA method compared with the HPLC method (0.05 and 0.5 ng ml-1, respectively). The RIA method was applied to the analysis of UK-68, 798 in plasma obtained from human volunteers receiving the compound.
引用
收藏
页码:141 / 149
页数:9
相关论文
共 50 条
  • [1] UK-68,798, A CLASS-III ANTIARRHYTHMIC DRUG WITH ANTIFIBRILLATORY PROPERTIES
    BLACK, SC
    LUCCHESI, BR
    CARDIOVASCULAR DRUG REVIEWS, 1992, 10 (02): : 170 - 181
  • [2] THE ANTIFIBRILLATORY ACTIONS OF UK-68,798, A CLASS-III ANTIARRHYTHMIC AGENT
    BLACK, SC
    CHI, LG
    MU, DX
    LUCCHESI, BR
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1991, 258 (02): : 416 - 423
  • [3] PHARMACOKINETIC AND PHARMACODYNAMIC EFFECTS OF UK-68,798, A NEW POTENTIAL CLASS-III ANTIARRHYTHMIC DRUG
    SEDGWICK, M
    RASMUSSEN, HS
    WALKER, D
    COBBE, SM
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (05) : 515 - 519
  • [4] PHARMACODYNAMICS AND PHARMACOKINETICS OF THE CLASS-III ANTIARRHYTHMIC AGENT DOFETILIDE (UK-68,798) IN HUMANS
    THAM, TCK
    MACLENNAN, BA
    BURKE, MT
    HARRON, DWG
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1993, 21 (03) : 507 - 512
  • [5] A DOSE-RANGING STUDY OF UK-68,798, A NOVEL CLASS-III ANTIARRHYTHMIC AGENT, IN NORMAL VOLUNTEERS
    GEMMILL, JD
    HOWIE, CA
    MEREDITH, PA
    KELMAN, AW
    RASMUSSEN, HS
    HILLIS, WS
    ELLIOTT, HL
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 32 (04) : 429 - 432
  • [6] CLINICAL AND ELECTROPHYSIOLOGIC EFFECTS OF INTRAVENOUS DOFETILIDE (UK-68,798), A NEW CLASS-III ANTIARRHYTHMIC DRUG, IN PATIENTS WITH ANGINA-PECTORIS
    SEDGWICK, ML
    RASMUSSEN, HS
    COBBE, SM
    AMERICAN JOURNAL OF CARDIOLOGY, 1992, 69 (05): : 513 - 517
  • [7] EFFECTS OF THE CLASS-III ANTIARRHYTHMIC, DOFETILIDE (UK-68,798) ON THE HEART-RATE OF MIDGESTATION RAT EMBRYOS, IN-VITRO
    SPENCE, SG
    VETTER, C
    HOE, CM
    TERATOLOGY, 1994, 49 (04) : 282 - 292
  • [8] ELECTROPHYSIOLOGIC PROFILE AND EFFICACY OF INTRAVENOUS DOFETILIDE (UK-68,798), A NEW CLASS-III ANTIARRHYTHMIC DRUG, IN PATIENTS WITH SUSTAINED MONOMORPHIC VENTRICULAR-TACHYCARDIA
    BASHIR, Y
    THOMSEN, PEB
    KINGMA, JH
    MOLLER, M
    WONG, C
    COBBE, SM
    JORDAENS, L
    CAMPBELL, RWF
    RASMUSSEN, HS
    CAMM, AJ
    AMERICAN JOURNAL OF CARDIOLOGY, 1995, 76 (14): : 1040 - 1044
  • [9] UK-68,798 - A NOVEL, POTENT AND HIGHLY SELECTIVE CLASS-III ANTIARRHYTHMIC AGENT WHICH BLOCKS POTASSIUM CHANNELS IN CARDIAC-CELLS
    GWILT, M
    ARROWSMITH, JE
    BLACKBURN, KJ
    BURGES, RA
    CROSS, PE
    DALRYMPLE, HW
    HIGGINS, AJ
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1991, 256 (01): : 318 - 324
  • [10] NEGATIVE CHRONOTROPIC EFFECT OF A NOVEL CLASS-III ANTIARRHYTHMIC DRUG, UK-68,798, DEVOID OF BETA-BLOCKING ACTION ON ISOLATED GUINEA-PIG ATRIA
    YANG, T
    TANDE, PM
    REFSUM, H
    BRITISH JOURNAL OF PHARMACOLOGY, 1991, 103 (02) : 1417 - 1420